Vertex 809-105

A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation. 

Purpose: Combo Therapy for Cystic Fibrosis homozygote genotype DeltaF508.


Sponsor: Vertex Pharmaceuticals


Principal Investigator: Cori Daines, MD


Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Study Status: